Cargando…
Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies
The pathetic malignant mesothelioma (MM) is a extremely uncommon and confrontational tumor that evolves in the mesothelium layer of the pleural cavities (inner lining- visceral pleura and outer lining- parietal pleura), peritoneum, pericardium, and tunica vaginalis and is highly resistant to standar...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353315/ https://www.ncbi.nlm.nih.gov/pubmed/37469419 http://dx.doi.org/10.3389/fonc.2023.1204722 |
_version_ | 1785074688947388416 |
---|---|
author | Sahu, Ram Kumar Ruhi, Sakina Jeppu, Ashok Kumar Al-Goshae, Husni Ahmed Syed, Ayesha Nagdev, Sanjay Widyowati, Retno Ekasari, Wiwied Khan, Jiyauddin Bhattacharjee, Bedanta Goyal, Manoj Bhattacharya, Sankha Jangde, Rajendra K. |
author_facet | Sahu, Ram Kumar Ruhi, Sakina Jeppu, Ashok Kumar Al-Goshae, Husni Ahmed Syed, Ayesha Nagdev, Sanjay Widyowati, Retno Ekasari, Wiwied Khan, Jiyauddin Bhattacharjee, Bedanta Goyal, Manoj Bhattacharya, Sankha Jangde, Rajendra K. |
author_sort | Sahu, Ram Kumar |
collection | PubMed |
description | The pathetic malignant mesothelioma (MM) is a extremely uncommon and confrontational tumor that evolves in the mesothelium layer of the pleural cavities (inner lining- visceral pleura and outer lining- parietal pleura), peritoneum, pericardium, and tunica vaginalis and is highly resistant to standard treatments. In mesothelioma, the predominant pattern of lesions is a loss of genes that limit tumour growth. Despite the worldwide ban on the manufacture and supply of asbestos, the prevalence of mesothelioma continues to increase. Mesothelioma presents and behaves in a variety of ways, making diagnosis challenging. Most treatments available today for MM are ineffective, and the median life expectancy is between 10 and 12 months. However, in recent years, considerable progress has already been made in understanding the genetics and molecular pathophysiology of mesothelioma by addressing hippo signaling pathway. The development and progression of MM are related to many important genetic alterations. This is related to NF2 and/or LATS2 mutations that activate the transcriptional coactivator YAP. The X-rays, CT scans, MRIs, and PET scans are used to diagnose the MM. The MM are treated with surgery, chemotherapy, first-line combination chemotherapy, second-line treatment, radiation therapy, adoptive T-cell treatment, targeted therapy, and cancer vaccines. Recent clinical trials investigating the function of surgery have led to the development of innovative approaches to the treatment of associated pleural effusions as well as the introduction of targeted medications. An interdisciplinary collaborative approach is needed for the effective care of persons who have mesothelioma because of the rising intricacy of mesothelioma treatment. This article highlights the key findings in the molecular pathogenesis of mesothelioma, diagnosis with special emphasis on the management of mesothelioma. |
format | Online Article Text |
id | pubmed-10353315 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103533152023-07-19 Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies Sahu, Ram Kumar Ruhi, Sakina Jeppu, Ashok Kumar Al-Goshae, Husni Ahmed Syed, Ayesha Nagdev, Sanjay Widyowati, Retno Ekasari, Wiwied Khan, Jiyauddin Bhattacharjee, Bedanta Goyal, Manoj Bhattacharya, Sankha Jangde, Rajendra K. Front Oncol Oncology The pathetic malignant mesothelioma (MM) is a extremely uncommon and confrontational tumor that evolves in the mesothelium layer of the pleural cavities (inner lining- visceral pleura and outer lining- parietal pleura), peritoneum, pericardium, and tunica vaginalis and is highly resistant to standard treatments. In mesothelioma, the predominant pattern of lesions is a loss of genes that limit tumour growth. Despite the worldwide ban on the manufacture and supply of asbestos, the prevalence of mesothelioma continues to increase. Mesothelioma presents and behaves in a variety of ways, making diagnosis challenging. Most treatments available today for MM are ineffective, and the median life expectancy is between 10 and 12 months. However, in recent years, considerable progress has already been made in understanding the genetics and molecular pathophysiology of mesothelioma by addressing hippo signaling pathway. The development and progression of MM are related to many important genetic alterations. This is related to NF2 and/or LATS2 mutations that activate the transcriptional coactivator YAP. The X-rays, CT scans, MRIs, and PET scans are used to diagnose the MM. The MM are treated with surgery, chemotherapy, first-line combination chemotherapy, second-line treatment, radiation therapy, adoptive T-cell treatment, targeted therapy, and cancer vaccines. Recent clinical trials investigating the function of surgery have led to the development of innovative approaches to the treatment of associated pleural effusions as well as the introduction of targeted medications. An interdisciplinary collaborative approach is needed for the effective care of persons who have mesothelioma because of the rising intricacy of mesothelioma treatment. This article highlights the key findings in the molecular pathogenesis of mesothelioma, diagnosis with special emphasis on the management of mesothelioma. Frontiers Media S.A. 2023-07-04 /pmc/articles/PMC10353315/ /pubmed/37469419 http://dx.doi.org/10.3389/fonc.2023.1204722 Text en Copyright © 2023 Sahu, Ruhi, Jeppu, Al-Goshae, Syed, Nagdev, Widyowati, Ekasari, Khan, Bhattacharjee, Goyal, Bhattacharya and Jangde https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Sahu, Ram Kumar Ruhi, Sakina Jeppu, Ashok Kumar Al-Goshae, Husni Ahmed Syed, Ayesha Nagdev, Sanjay Widyowati, Retno Ekasari, Wiwied Khan, Jiyauddin Bhattacharjee, Bedanta Goyal, Manoj Bhattacharya, Sankha Jangde, Rajendra K. Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies |
title | Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies |
title_full | Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies |
title_fullStr | Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies |
title_full_unstemmed | Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies |
title_short | Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies |
title_sort | malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353315/ https://www.ncbi.nlm.nih.gov/pubmed/37469419 http://dx.doi.org/10.3389/fonc.2023.1204722 |
work_keys_str_mv | AT sahuramkumar malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies AT ruhisakina malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies AT jeppuashokkumar malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies AT algoshaehusniahmed malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies AT syedayesha malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies AT nagdevsanjay malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies AT widyowatiretno malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies AT ekasariwiwied malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies AT khanjiyauddin malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies AT bhattacharjeebedanta malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies AT goyalmanoj malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies AT bhattacharyasankha malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies AT jangderajendrak malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies |